Latest & greatest articles for divalproex

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on divalproex or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on divalproex and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for divalproex

1. Divalproex

Divalproex Top results for divalproex - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for divalproex The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you

2018 Trip Latest and Greatest

2. Efficacy and Safety of Asenapine Versus Olanzapine in Combination With Divalproex for Acute Mania: A Randomized Controlled Trial. (Abstract)

Efficacy and Safety of Asenapine Versus Olanzapine in Combination With Divalproex for Acute Mania: A Randomized Controlled Trial. Atypical antipsychotics are used for the treatment of acute mania, either as monotherapy or in combination with lithium or divalproex, which have a better tolerability profile as compared with typical antipsychotics. Asenapine, a newer atypical antipsychotic, has been found to be effective for the treatment of mania, with efficacy similar to olanzapine. The objective (...) of the study was to compare the efficacy and safety of asenapine and olanzapine when used in combination with divalproex in patients with acute mania.One hundred twenty patients aged 18 to 55 years, diagnosed with manic episode, were randomized to receive either flexible dose of sublingual asenapine (10-20 mg/d) or tablet olanzapine (10-20 mg/d), in combination with valproate 20 mg/kg per day for a period of 6 weeks. Efficacy was measured as change in Young Mania Rating Scale and Clinical Global Impression

2019 Journal of Clinical Psychopharmacology Controlled trial quality: uncertain

3. Comparing the Effects of Atorvastatin With Sodium Valproate (Divalproex) on Frequency and Intensity of Frequent Migraine Headaches: A Double-blind Randomized Controlled Study. (Abstract)

Comparing the Effects of Atorvastatin With Sodium Valproate (Divalproex) on Frequency and Intensity of Frequent Migraine Headaches: A Double-blind Randomized Controlled Study. To evaluate the prophylactic effects of atorvastatin on frequency, intensity, and duration of migraine attacks compared with sodium valproate.In this randomized, double-blind, single-center controlled trial, patients with 6 to 15 migraine attacks per month, which were candidates of preventive treatment, were recruited

2018 Clinical neuropharmacology Controlled trial quality: uncertain

4. Divalproex versus valproate in patients with bipolar disorder. (Abstract)

Divalproex versus valproate in patients with bipolar disorder. 15206673 2004 07 06 2013 11 21 0271-0749 24 2 2004 Apr Journal of clinical psychopharmacology J Clin Psychopharmacol Divalproex versus valproate in patients with bipolar disorder. 231-2 Kablinger Anita S AS Czerwinski Witold P WP Minagar Alireza A eng Clinical Trial Comparative Study Letter Multicenter Study Randomized Controlled Trial United States J Clin Psychopharmacol 8109496 0271-0749 0 Antimanic Agents 614OI1Z5WI Valproic Acid

2004 Journal of Clinical Psychopharmacology Controlled trial quality: uncertain

5. Divalproex Sodium in the Treatment of PTSD (Post-Traumatic Stress Disorder)

Divalproex Sodium in the Treatment of PTSD (Post-Traumatic Stress Disorder) Divalproex Sodium in the Treatment of PTSD (Post-Traumatic Stress Disorder) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Divalproex Sodium in the Treatment of PTSD (Post-Traumatic Stress Disorder) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00108576 Recruitment Status : Completed First Posted : April 18, 2005 Last Update Posted : October 21, 2015 Sponsor: VA Office of Research and Development Information provided

2005 Clinical Trials

6. Maintenance Phase Treatment With Divalproex for Post Traumatic Stress Disorder

Maintenance Phase Treatment With Divalproex for Post Traumatic Stress Disorder Maintenance Phase Treatment With Divalproex for Post Traumatic Stress Disorder - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Maintenance Phase Treatment With Divalproex for Post Traumatic Stress Disorder The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00203385 Recruitment Status : Terminated (Funding expired) First Posted : September 20, 2005 Last Update Posted : April 26, 2017 Sponsor: Tuscaloosa Research & Education

2005 Clinical Trials

7. Divalproex sodium for the treatment of PTSD and conduct disordered youth: a pilot randomized controlled clinical trial. (Abstract)

Divalproex sodium for the treatment of PTSD and conduct disordered youth: a pilot randomized controlled clinical trial. We examined the efficacy of divalproex sodium (DVP) for the treatment of PTSD in conduct disorder, utilizing a previous study in which 71 youth were enrolled in a randomized controlled clinical trial. Twelve had PTSD. Subjects (all males, mean age 16, SD 1.0) were randomized into high and low dose conditions. Clinical Global Impression (CGI) ratings for core PTSD symptoms

2007 Child psychiatry and human development Controlled trial quality: uncertain

8. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Full Text available with Trip Pro

Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Agitation and psychosis are common in Alzheimer disease and cause considerable morbidity. We attempted to delay or to prevent agitation and psychosis with the use of divalproex sodium (valproate).To determine whether treatment with valproate could delay or prevent emergence of agitation or psychosis.A multicenter, randomized, double-blind, placebo-controlled trial of flexible-dose valproate in 313

2011 Archives of general psychiatry Controlled trial quality: predicted high

9. Aripiprazole plus divalproex for recently manic or mixed patients with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind maintenance trial. (Abstract)

Aripiprazole plus divalproex for recently manic or mixed patients with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind maintenance trial. The goal of this study was to investigate the safety and efficacy in preventing relapse of a mood episode in recently manic or mixed episode patients with bipolar I disorder stabilized with aripiprazole and divalproex combination.This randomized, 24-week, double-blind, placebo-controlled multicenter study enrolled patients from 23 (...) centers in Korea. Patients with bipolar I disorder who had manic or mixed episode entered a 6-week open-label stabilization phase. After meeting stabilization criteria, 83 patients were randomly assigned to placebo + divalproex or aripiprazole + divalproex treatment group for the 24-week, double-blind maintenance phase.During the 6-month double-blind treatment, the time to relapse of any mood episode in the aripiprazole group was longer than the placebo group, but the difference did not reach

2011 Human psychopharmacology Controlled trial quality: uncertain

10. Divalproex sodium (Depakote) for alcohol withdrawal and relapse prevention. (Abstract)

Divalproex sodium (Depakote) for alcohol withdrawal and relapse prevention. This pilot study evaluates the safety and efficacy of divalproex sodium (Depakote) for alcohol withdrawal and relapse prevention. Sixteen patients in moderate alcohol withdrawal were randomized to receive a standard benzodiazepine detoxification, depakote detoxification, or depakote detox plus maintenance. Symptom reduction occurred more rapidly and consistently in the depakote treated patients than (...) in the benzodiazepine control group, and at six-week follow up a greater percentage of patients in the depakote maintenance group were completely abstinent than either detox-only group. There were no significant differences in sociodemographic or drinking data amongst the three cohort samples at baseline. Our findings suggest that the anticonvulsant divalproex sodium (Depakote) may be a safe and efficacious alternative to benzodiazepines for the treatment of alcohol withdrawal. It may be an advantageous alternative

2002 Journal of addictive diseases Controlled trial quality: uncertain

11. Long-term outcome with divalproex in children and adolescents with bipolar disorder. (Abstract)

Long-term outcome with divalproex in children and adolescents with bipolar disorder. To assess the outcome and safety of divalproex treatment in children and adolescents with bipolar disorder.We conducted a chart review of children and adolescents who were treated with divalproex and who met Diagnostic and Statistical Manual of Mental Disorders, fourth edition, criteria for bipolar disorder (dose 966 +/- 501 mg/day, level 79.4 +/- 23.1 micro g/mL, duration 1.4 +/- 1.5 years). Responders were (...) defined as those showing moderate to marked response on the Clinical Global Impression-Improvement (CGI-I) scale.Eight of 15 (53%) patients responded to divalproex treatment for mixed episode (n = 6), disruptive behavior (n = 4), pure mania (n = 3), or depression (n = 2). Six of 15 (40%) discontinued divalproex, most due to side effects (n = 5). The most common side effect was weight gain (4/15, 27%).In children aged 4-18 years, divalproex treatment was related to improved outcome in the long-term

1 Journal of Child and Adolescent Psychopharmacology

12. Oxcarbazepine versus Divalproex Sodium for the Continuing Treatment of Mania. (Abstract)

Oxcarbazepine versus Divalproex Sodium for the Continuing Treatment of Mania. Oxcarbazepine, an antiepileptic and a derivative of carbamazepine, has been shown to have clinical utility as an antimanic agent. This study sought to assess the efficacy and tolerability of oxcarbazepine compared with divalproex sodium in the treatment of patients with mania.57 patients from a large clinical practice who had recently begun treatment with divalproex sodium were randomly assigned to one of two (...) treatment groups. In this open-label, single (rater)-blind study, group 1 remained on treatment with divalproex sodium and group 2 was switched to oxcarbazepine. Both treatment groups were followed for 10 weeks after the switch. Pharmacotherapeutic efficacy was compared using the Clinician Administered Rating Scale for Mania (CARS-M). Weight and adverse events were monitored throughout the study.83% of patients using oxcarbazepine showed a decrease in mania as assessed using the CARS-M, and 70% showed

2007 Clinical drug investigation Controlled trial quality: uncertain

13. Determinants of free serum valproate concentration: A prospective study in patients on divalproex sodium monotherapy. Full Text available with Trip Pro

Determinants of free serum valproate concentration: A prospective study in patients on divalproex sodium monotherapy. To evaluate variables affecting the valproate (VPA) free fraction and develop an equation for computing free VPA concentration from total VPA concentration.Trough total and free VPA concentrations were collected from patients who participated in a prospective VPA monotherapy trial. All available paired data of trough total and free VPA concentrations were included. Significant

2018 Seizure Controlled trial quality: uncertain

14. A multiphasic absorption model best characterizes gastrointestinal absorption of divalproex sodium extended-release tablets. (Abstract)

A multiphasic absorption model best characterizes gastrointestinal absorption of divalproex sodium extended-release tablets. 16855080 2006 12 01 2014 11 20 0091-2700 46 8 2006 Aug Journal of clinical pharmacology J Clin Pharmacol A multiphasic absorption model best characterizes gastrointestinal absorption of divalproex sodium extended-release tablets. 952-7 Dutta Sandeep S Abbott Laboratories, Dept. R4PK, Bldg. AP13A, 100 Abbott Park Road, Abbott Park IL 60064-6104, USA. Sandeep.Dutta

2006 Journal of clinical pharmacology Controlled trial quality: uncertain

15. Divalproex versus placebo for the prevention of irritability associated with fluoxetine treatment in autism spectrum disorder. (Abstract)

Divalproex versus placebo for the prevention of irritability associated with fluoxetine treatment in autism spectrum disorder. 16855475 2006 09 18 2013 11 21 0271-0749 26 4 2006 Aug Journal of clinical psychopharmacology J Clin Psychopharmacol Divalproex versus placebo for the prevention of irritability associated with fluoxetine treatment in autism spectrum disorder. 444-6 Anagnostou Evdokia E Esposito Katherine K Soorya Latha L Chaplin William W Wasserman Stacey S Hollander Eric E eng Letter

2006 Journal of Clinical Psychopharmacology Controlled trial quality: uncertain

16. Efficacy of Quetiapine XR Versus Divalproex on Clinical Outcome Quality of Sleep and Quality of Life in Bipolar Depression

Efficacy of Quetiapine XR Versus Divalproex on Clinical Outcome Quality of Sleep and Quality of Life in Bipolar Depression Efficacy of Quetiapine XR Versus Divalproex on Clinical Outcome Quality of Sleep and Quality of Life in Bipolar Depression - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached (...) the maximum number of saved studies (100). Please remove one or more studies before adding more. Efficacy of Quetiapine XR Versus Divalproex on Clinical Outcome Quality of Sleep and Quality of Life in Bipolar Depression The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01587066 Recruitment Status : Withdrawn

2012 Clinical Trials

17. Acute hyponatremia with accompanying hyperammonemia secondary to divalproex sodium: A case report Full Text available with Trip Pro

Acute hyponatremia with accompanying hyperammonemia secondary to divalproex sodium: A case report Divalproex sodium (DVP) is an antiepileptic medication that also has mood stabilizing properties for patients with mental health disorders. Currently, there are a small number of case reports discussing the incidence of hyponatremia that occurs as an adverse effect of DVP. After completion of a thorough literature search, we present the first case report describing acute hyponatremia

2018 The Mental Health Clinician

18. GERI-BD: A Randomized Double-Blind Controlled Trial of Lithium and Divalproex in the Treatment of Mania in Older Patients With Bipolar Disorder. Full Text available with Trip Pro

GERI-BD: A Randomized Double-Blind Controlled Trial of Lithium and Divalproex in the Treatment of Mania in Older Patients With Bipolar Disorder. Clinicians treating older patients with bipolar disorder with mood stabilizers need evidence from age-specific randomized controlled trials. The authors describe findings from a first such study of late-life mania.The authors compared the tolerability and efficacy of lithium carbonate and divalproex in 224 inpatients and outpatients age 60 or older (...) with bipolar I disorder who presented with a manic, hypomanic, or mixed episode. Participants were randomly assigned, under double-blind conditions, to treatment with lithium (target serum concentration, 0.80-0.99 mEq/L) or divalproex (target serum valproate concentration, 80-99 μg/mL) for 9 weeks. Participants with an inadequate response after 3 weeks received open adjunctive risperidone. The authors hypothesized that divalproex would be better tolerated and more efficacious than lithium. Tolerability

2017 American Journal of Psychiatry Controlled trial quality: predicted high

19. Release property study on the novel divalproex sodium enteric-coated capsules Full Text available with Trip Pro

Release property study on the novel divalproex sodium enteric-coated capsules In the present study, a novel divalproex sodium (DS) enteric-coated capsule was prepared, and high performance liquid chromatography (HPLC) assay method for DS was developed. Their uniformity, release curve and release characteristics in different solvents were examined. The release studies were performed using marketed sample as a reference and data were analyzed in terms of cumulative release amounts as a function

2016 Saudi Pharmaceutical Journal : SPJ

20. Adding mixed amphetamine salts to divalproex sodium improves ADHD symptoms in children with bipolar disorder and comorbid ADHD Full Text available with Trip Pro

Adding mixed amphetamine salts to divalproex sodium improves ADHD symptoms in children with bipolar disorder and comorbid ADHD Adding mixed amphetamine salts to divalproex sodium improves ADHD symptoms in children with bipolar disorder and comorbid ADHD | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Adding mixed amphetamine salts to divalproex sodium improves ADHD symptoms in children with bipolar disorder and comorbid ADHD Article Text

2006 Evidence-Based Mental Health